Gene therapy (IL-12/IFN-alpha, PINC), Valentis

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameGene therapy (IL-12/IFN-alpha, PINC), Valentis
Drug Alias Namegene therapy (interleukin-12/ interferon-alpha, PINC)
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionInterferon alpha modulators
TargetsInterferon alpha
Therapy Area/IndicationsHead and Neck NeoplasmsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUrigenF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUrigenF. Hoffmann-La Roche Ltd
Active IndicationsN/A
Inactive IndicationsHead and Neck NeoplasmsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A